FOLH1 and posterior cortical atrophy: During the last years, [177Lu]Lu-PSMA-617 has been involved in several clinical trials for radioligand therapy (RLT) of PCa [21,22] and very recently, [177Lu]Lu-PSMA-617 was approved by the FDA as the first targeted RLT for treatment of progressive PSMA-positive metastatic castration-resistant PCa [24].